Justin Thompson, MS

Justin R. Thompson, MS is an experienced professional with over 20 years of business development and strategic investments in the life sciences and venture capital industry. Justin founded JucaBio in April 2023.

Justin led the business development function of CinCor Pharma, Inc., a clinical-stage biotech, from its formation through the in-licensing of baxdrostat from Roche, culminating in its acquisition by AstraZeneca for up to $1.8 billion in early 2023. Justin, in conjunction with Dr. Pearce, led the in-licensing of baxdrostat in 2019.  Prior to CinCor, he served as the Chief Business Officer at CinRx Pharma, LLC, leading additional licensing and venture transactions.  He was also a Principal investor at CincyTech, LLC, a public-private seed-stage investor focused on high-growth life science and technology companies.

Justin has demonstrated key skills in business development, strategic investments, and leadership. He has successfully led the in-licensing of key assets, managed strategic partnerships, and driven significant growth and acquisitions. His strategic vision and leadership have been pivotal in achieving major milestones, including successful acquisitions and the establishment of robust investment frameworks. Additionally, Justin’s expertise in strategic investments has helped numerous life science companies establish strong financial and operational foundations.

Justin holds an M.S. from the University of Cincinnati and a B.S. from Washington University in St. Louis. In his personal life, he enjoys spending time with his family and almost anything outdoors.